Peptide 'glow' claims on TikTok: what the science says

What's this video probably claiming?

With a caption like "I be glowing" and a category rooted in peptide therapy, @ohmysebb is almost certainly crediting a peptide protocol, likely GHK-Cu, BPC-157, or possibly a growth hormone secretagogue stack like CJC-1295 with ipamorelin, for visible skin improvements. This fits a well-worn TikTok formula: creator looks radiant, implies a peptide is responsible, lets the comments fill in the gaps. The "glow" framing is strategically vague. It could mean better skin texture, reduced inflammation, faster healing, or simply looking rested. That vagueness is doing a lot of regulatory heavy lifting. Without a transcript we cannot confirm specific claims, but the peptide category tag and aesthetic framing make the direction fairly predictable.

What does the science actually show?

GHK-Cu (copper tripeptide-1) has the most directly relevant skin data. Leyden et al. (2008, Journal of Cosmetic Dermatology) found topical GHK-Cu improved skin laxity and reduced wrinkle depth in a double-blind trial over 12 weeks, though the effect sizes were modest and the formulations were cosmetic-grade, not injected peptides. Pickart and Margolina (2018, Cosmetics) reviewed GHK-Cu's role in collagen synthesis stimulation and antioxidant gene expression, which sounds impressive until you notice most cited mechanisms are in vitro or animal data. Growth hormone secretagogues like CJC-1295 do increase IGF-1 levels, and IGF-1 has documented roles in skin cell turnover, but no randomized controlled trials have tested CJC-1295 specifically for cosmetic skin outcomes in healthy adults. The glow is biologically plausible. It is not clinically proven.

Where does the social media noise diverge from clinical reality?

The gap here is the difference between "biologically plausible" and "clinically demonstrated in humans at safe doses." TikTok peptide content routinely collapses that distinction. GHK-Cu injected subcutaneously is not the same compound studied in topical cosmetic trials, and the pharmacokinetics differ significantly. BPC-157, another common "glow" peptide on social media, has zero completed human RCTs for skin outcomes as of early 2025. Its healing data comes from rodent models (Seiwerth et al., 2018, Current Pharmaceutical Design). MK-677, frequently stacked with these protocols, is an oral ghrelin mimetic that raises IGF-1 but also causes water retention, increased appetite, and potential insulin resistance with extended use. That puffy, well-fed look can read as a glow. It is not the same as documented collagen remodeling.

What should you actually know?

If you are considering peptides for skin quality, the honest picture is this: some have credible mechanistic rationale, most lack the human trial data to support confident cosmetic claims, and none are FDA-approved for aesthetic indications. GHK-Cu in topical form has the strongest cosmetic evidence base, though effect sizes in trials are rarely dramatic. Injectable peptide protocols carry real risks including injection site reactions, hormonal disruption with secretagogues, and sourcing quality issues since most are compounded or research-grade. The "glow" you see on a creator's face after a peptide protocol is confounded by lighting, skincare routines, sleep, diet, and the simple fact that people who invest in peptide therapy often invest in their health broadly. Correlation is not causation, even when someone looks genuinely great on camera.